The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors
Open accessAbstract
Whereas over 85% of human cancers are solid tumors, of the 8 monoclonal antibodies (mAbs) currently approved for cancer therapy, 25% are directed at solid tumor surface antigens (Ags). This shortfall may be due to barriers to achieving adequate exposure in solid tumors. Advancements in tumor biology, protein engineering, and theoretical modeling of macromolecular transport are currently enabling identification of critical physical properties for antitumor Abs. It is now possible to structurally modify Abs or even replace full Abs with a plethora of Ab constructs. These constructs include Fab and Fab′2 fragments, scFvs, multivalent scFvs (e.g., diabodies and tribodies), minibodies (e.g., scFv‐CH3 dimers), bispecific Abs, and camel variable functional heavy chain domains. The purpose of the article is to provide investigators with a conceptual framework for exploiting the recent scientific advancements. The focus is on 2 properties that govern tumor exposure: 1) physical properties that enable penetration of and retention by tumors, and 2) favorable plasma pharmacokinetics. It is demonstrated that manipulating molecular size, charge, valence, and binding affinity can optimize these properties. These manipulations hold the key to promoting tumor exposure and to ultimately creating successful Ab therapies for solid tumors. Cancer 2007. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Self-citationRole of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Shields, R. L., Namenuk, A. K., Hong, K., Meng, Y. G., Rae, J., Briggs, J., Xie, D., Lai, J., Stadlen, A., Li, B., et al. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m009483200 · Cited by 1,161
Antibody Pharmacokinetics and Pharmacodynamics
Lobo, E. D., Hansen, R. J., & Balthasar, J. P. (2004) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20178 · Cited by 909
Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection
Baxter, L. T., & Jain, R. K. (1989) · Microvascular Research · doi:10.1016/0026-2862(89)90074-5 · Cited by 894
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
(1990) · PubMed · Cited by 757
Jain, R. K., & Baxter, L. T. (1988) · PubMed · Cited by 714
Adams, G. P., Schier, R., McCall, A. M., Simmons, H. H., Horak, E. M., Alpaugh, R. K., Marks, J. D., & Weiner, L. M. (2001) · PubMed · Cited by 629
Self-citationMicrovascular permeability of normal and neoplastic tissues
Gerlowski, L. E., & Jain, R. K. (1986) · Microvascular Research · doi:10.1016/0026-2862(86)90018-x · Cited by 622
Pluen, A., Boucher, Y., Ramanujan, S., McKee, T. D., Gohongi, T., di Tomaso, E., Brown, E. B., Izumi, Y., Campbell, R. B., Berk, D. A., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081626898 · Cited by 603
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.
Jain, R. K. (1990) · PubMed · Cited by 574
Ober, R. J., Radu, C. G., Ghetie, V., & Ward, E. S. (2001) · International Immunology · doi:10.1093/intimm/13.12.1551 · Cited by 501
Drug Delivery and Transport to Solid Tumors
Jang, S. H., Wientjes, M. G., Lu, D., & Au, J. L.-S. (2003) · Pharmaceutical Research · doi:10.1023/a:1025785505977 · Cited by 483
Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., & Schnitzer, J. E. (2004) · Nature · doi:10.1038/nature02580 · Cited by 475
Durr, E., Yu, J., Krasinska, K. M., Carver, L. A., Yates, J. R., Testa, J. E., Oh, P., & Schnitzer, J. E. (2004) · Nature Biotechnology · doi:10.1038/nbt993 · Cited by 420
Transport of fluid and macromolecules in tumors
Baxter, L. T., & Jain, R. K. (1991) · Microvascular Research · doi:10.1016/0026-2862(91)90003-t · Cited by 368
A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier.
Fujimori, K., Covell, D. G., Fletcher, J. E., & Weinstein, J. N. (1990) · PubMed · Cited by 356
Hu, S., Shively, L., Raubitschek, A. A., Sherman, M. A., Williams, L. E., Wong, J. Y., Shively, J. E., & Wu, A. M. (1996) · PubMed · Cited by 330
Rowinsky, E. K., Schwartz, G. H., Gollob, J. A., Thompson, J. A., Vogelzang, N. J., Figlin, R., Bukowski, R., Haas, N., Lockbaum, P., Li, Y.-P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.061 · Cited by 329
Kim, J., Hake, S. B., & Roeder, R. G. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.11.012 · Cited by 317
Extravascular diffusion in normal and neoplastic tissues.
Nugent, L. J., & Jain, R. K. (1984) · PubMed · Cited by 316
Adams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., & Sliwkowski, M. X. (2006) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-005-0058-x · Cited by 316
Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
Covell, D. G., Barbet, J., Holton, O. D., BLACK, C. D. V., Parker, R. J., & Weinstein, J. N. (1986) · PubMed · Cited by 311
Baxter, L. T., Zhu, H. J., Mackensen, D. G., & Jain, R. K. (1994) · PubMed · Cited by 284
Efficient tumor targeting by single‐domain antibody fragments of camels
Cortez‐Retamozo, V., Lauwereys, M., Hassanzadeh Gh., G., Gobert, M., Conrath, K., Muyldermans, S., De Baetselier, P., & Revets, H. (2002) · International Journal of Cancer · doi:10.1002/ijc.10212 · Cited by 260
Lin, Y. S., Nguyen, C., Mendoza, J.-L., Escandon, E., Fei, D., Meng, Y. G., & Modi, N. B. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37962-5 · Cited by 255
(1992) · PubMed · Cited by 252
(1992) · PubMed · Cited by 247
Delacroix, D. L., Hodgson, H. J., McPherson, A., Dive, C., & Vaerman, J. P. (1982) · Journal of Clinical Investigation · doi:10.1172/jci110610 · Cited by 234
Sundaresan, G., Yazaki, P. J., Shively, J. E., Finn, R. D., Larson, S. M., Raubitschek, A. A., Williams, L. E., Chatziioannou, A. F., Gambhir, S. S., & Wu, A. M. (2003) · PubMed · Cited by 222
Adams, G., Schier, R., McCall, A., Crawford, R., Wolf, E., Weiner, L., & Marks, J. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.233 · Cited by 208
Self-citationGraff, C. P., & Wittrup, K. D. (2003) · PubMed · Cited by 205
Junghans, R. P. (1997) · Immunologic Research · doi:10.1007/bf02786322 · Cited by 205
Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers
Wu, A. M., Chen, W., Raubitschek, A., Williams, L. E., Neumaier, M., Fischer, R., Hu, S.-Z., Odom-Maryon, T., Wong, J. Y. C., & Shively, J. E. (1996) · Immunotechnology · doi:10.1016/1380-2933(95)00027-5 · Cited by 198
Posey, J. A., Khazaeli, M. B., DelGrosso, A., Saleh, M. N., Lin, C. Y., Huse, W., & LoBuglio, A. F. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801300189218 · Cited by 190
Crystal structure of a diabody, a bivalent antibody fragment
Perisic, O., Webb, P. A., Holliger, P., Winter, G., & Williams, R. L. (1994) · Structure · doi:10.1016/s0969-2126(94)00123-5 · Cited by 189
Baxter, L. T., Zhu, H. J., Mackensen, D. G., Butler, W. F., & Jain, R. K. (1995) · PubMed · Cited by 180
Roh, H., Boucher, Y., Kalnicki, S., Buchsbaum, R., Bloomer, W. D., & Jain, R. K. (1991) · PubMed · Cited by 180
Antibody Engineering for the Development of Therapeutic Antibodies
Kim, S. J., Park, Y., & Hong, H. J. (2005) · Molecules and Cells · doi:10.1016/s1016-8478(23)25245-0 · Cited by 167
Genetic instability in cancer: Theory and experiment
BECKMAN, R., & Loeb, L. A. (2005) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2005.06.007 · Cited by 150
Self-citationBaxter, L. T., & Jain, R. K. (1991) · Microvascular Research · doi:10.1016/0026-2862(91)90026-8 · Cited by 144
Pharmacokinetics and biodistribution of genetically-engineered antibodies.
Colcher, D. M., Pavlínková, G., Beresford, G., Booth, B. J. M., Choudhury, A., & Batra, S. K. (1998) · PubMed · Cited by 143
Tunggal, J. K., Cowan, D., Shaikh, H., & Tannock, I. F. (1999) · PubMed · Cited by 133
Quantitative Techniques for Study of the Anatomy and Function of Small Blood Vessels in Tumors
Tannock, I. F., & Steel, G. G. (1969) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/42.5.771 · Cited by 129
Fox, J. A., Hotaling, T. E., Struble, C. B., Ruppel, J., Bates, D. J., & Schoenhoff, M. (1996) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)21215-0 · Cited by 123
Interstitial transport of rabbit and sheep antibodies in normal and neoplastic tissues.
Clauss, M. A., & Jain, R. K. (1990) · PubMed · Cited by 110
Nielsen, U. B., Adams, G. P., Weiner, L. M., et al. (2000) · PubMed · Cited by 110
Self-citationWeinstein, J. N., & van Osdol, W. (1992) · PubMed · Cited by 104
Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv Dimers
Adams, G. P., Tai, M.-S., McCartney, J. E., Marks, J. D., Stafford, W. F., Houston, L. L., Huston, J. S., & Weiner, L. M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2217 · Cited by 100
Self-citationBallangrud, Å., Yang, W., Charlton, D. E., McDevitt, M. R., Hamacher, K. A., Panageas, K. S., Ma, D., Bander, N. H., Scheinberg, D. A., & Sgouros, G. (2001) · PubMed · Cited by 98
Verel, I., Heider, K., Siegmund, M., Ostermann, E., Patzelt, E., Sproll, M., Snow, G. B., Adolf, G. R., & van Dongen, G. A. M. S. (2002) · International Journal of Cancer · doi:10.1002/ijc.10369 · Cited by 87
Future of Monoclonal Antibodies in the Treatment of Hematologic Malignancies
Reff, M. E., Hariharan, K., & Braslawsky, G. R. (2002) · Cancer Control · doi:10.1177/107327480200900207 · Cited by 83
Dowling, T. C., Chavaillaz, P., Young, D. G., Melton‐Celsa, A. R., O’Brien, A. D., Thuning-Roberson, C., Edelman, R., & Tacket, C. O. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.5.1808-1812.2005 · Cited by 72
Albrecht, H., Burke, P. A., Natarajan, A., Xiong, C.-Y., Kalicinsky, M., DeNardo, G. L., & DeNardo, S. J. (2003) · Bioconjugate Chemistry · doi:10.1021/bc030018+ · Cited by 72
Protein Pharmacokinetics and Metabolism
Ferraiolo, B. L., Mohler, M. A., & Gloff, C. A. (1992) · Pharmaceutical biotechnology · doi:10.1007/978-1-4899-2329-5 · Cited by 71
ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas
Bono, J. S. D., Tolcher, A. W., Forero-Torres, A., Vanhove, G. F. A., Takimoto, C. H. M., Bauer, R. J., Hammond, L. A., Patnaik, A., White, M., Shen, S., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0729 · Cited by 67
Zhou, J., Johnson, J. E., Ghetie, V. F., Ober, R. J., & Ward, E. S. (2003) · Journal of Molecular Biology · doi:10.1016/s0022-2836(03)00952-5 · Cited by 65
Kloft, C., Graefe, E.-U., Tanswell, P., Scott, A. M., Hofheinz, R., Amelsberg, A., & Karlsson, M. O. (2003) · Investigational New Drugs · doi:10.1023/b:drug.0000006173.72210.1c · Cited by 64
Blumenthal, R. D., Fand, I., Sharkey, R. M., et al. (1991) · Cancer Immunology Immunotherapy · doi:10.1007/bf01741594 · Cited by 57
Chow, F., Benincosa, L. J., Sheth, S. B., Wilson, D., Davis, C. B., Minthorn, E. A., & Jusko, W. J. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122276 · Cited by 49
(2025) · Beiträge zur Onkologie/Contributions to oncology · doi:10.1159/issn.0250-3220 · Cited by 49
Irradiation reduces interstitial fluid transport and increases the collagen content in tumors.
Znati, C. A., Rosenstein, M., McKee, T. D., Brown, E. B., Turner, D., Bloomer, W. D., Watkins, S. C., Jain, R. K., & Boucher, Y. (2003) · PubMed · Cited by 48
Langmuir, V. K., Mendonca, H. L., & Woo, D. V. (1992) · PubMed · Cited by 47
Melkko, S., Halin, C., Borsi, L., Zardi, L., & Neri, D. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)03927-5 · Cited by 43
Tahtis, K., Lee, F.-T., Smyth, F. E., Power, B. E., Renner, C., Brechbiel, M. W., Old, L. J., Hudson, P. J., & Scott, A. M. (2001) · PubMed · Cited by 38
Slowed diffusion in tumors revealed by microfiberoptic epifluorescence photobleaching
Thiagarajah, J. R., Kim, J. K., Magzoub, M. M., & Verkman, A. S. (2006) · Nature Methods · doi:10.1038/nmeth863 · Cited by 34
Khawli, L. A., Biela, B. H., Hu, P., & Epstein, A. L. (2003) · Hybridoma and Hybridomics · doi:10.1089/153685903321538026 · Cited by 33
Hjelstuen, M. H. B., Rasch-Halvorsen, K., Brekken, C., Bruland, Ø. S., & Davies, C. D. L. (1996) · Acta Oncologica · doi:10.3109/02841869609101641 · Cited by 17
Time‐resolved confocal analysis of antibody penetration into living, solid tumor spheroids
Myrdal, S. E., & Foster, M. (1994) · Scanning · doi:10.1002/sca.4950160316 · Cited by 17
Olabiran, Y., Ledermann, J. A., Marston, N., Boxer, G., Hicks, R. J., Souhami, R. L., Spiro, S. G., & Stahel, R. A. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.47 · Cited by 13
Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies
Ternant, D., Ohresser, M. C. P., Thomas, C., Cartron, G., Watier, H., & Paintaud, G. (2005) · Blood · doi:10.1182/blood-2005-02-0798 · Cited by 11
Antibody targeting studies in a transgenic murine model of spontaneous colorectal tumors
Wilkinson, R. W., Ross, E. L., Poulsom, R., Ilyas, M., Straub, J., Snary, D., Bodmer, W. F., & Mather, S. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181353498 · Cited by 11
Storto, G., Buchegger, F., Waibel, R., Künzi, G., Offord, R. E., Schubiger, P. A., Gillet, M., & Delaloye, A. B. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801753354276 · Cited by 10
Cited by
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
The therapeutic potential of nanobodies
Jovčevska, I., & Muyldermans, S. (2020) · BioDrugs · doi:10.1007/s40259-019-00392-z · Cited by 749
ErbB receptors: from oncogenes to targeted cancer therapies
Zhang, H., Berezov, A., Wang, Q., Zhang, G., Drebin, J., Murali, R., & Greene, M. I. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32278 · Cited by 574
Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics
Bannas, P., Hambach, J., & Koch-Nolte, F. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01603 · Cited by 572
Engineered SIRPα Variants as Immunotherapeutic Adjuvants to Anticancer Antibodies
Weiskopf, K., Ring, A. M., Ho, C. C. M., Volkmer, J.-P., Levin, A. M., Volkmer, A. K., Özkan, E., Fernhoff, N. B., van de Rijn, M., Weissman, I. L., et al. (2013) · Science · doi:10.1126/science.1238856 · Cited by 495
Metadata
- Authors
- Beckman, R. A., Weiner, L. M., & Davis, H. M.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2007-01-08
- Volume
- 109
- Issue
- 2
- Pages
- 170-179
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2045882462
- Cited by
- 281
- References
- 76
- FWCI
- 8.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.